In the AMBER trial, taking concomitant patiromer enabled more persistent use of spironolactone in patients with resistant hypertension and chronic kidney disease, by reducing the risk of hyperkalemia.
ESC 2019 A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.
In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.
ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.
An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.
First-in-class firibastat, a selective and specific inhibitor of brain aminopeptidase A, safely reduced BP in hypertensive, overweight patients of multiple ethnic origins.
Analysis of data of six randomized sham-controlled trials of renal sympathetic denervation, shows that RSD gave greater reduction in 24-h ambulatory, daytime ambulatory and office SBP and DBP.
ONTARGET and TRANSCEND data show a non-linear association between mean achieved SBP and DBP and clinical outcomes, and event risk was higher in diabetes vs. no diabetes, across the BP spectrum
ACC 2019 The randomized INFINITY trial showed a significant reduction in accrual of subcortical white matter disease in older people receiving more intensive antihypertensive therapy, but mobility and cognitive function were not improved.
An exploratory analysis of SPRINT data using a machine learning method identified a subgroup of smokers with baseline SBP >144 mmHg who had a higher rate of CV events and acute kidney injury with an SBP treatment target of <120 mmHg vs 140 mmHg.
In the SPYRAL HTN-OFF MED study, RDN lowered HR, particularly in the morning. Patients with HR above the median showed a greater drop in HR and BP than those with lower HR at baseline.